Evidence map›Paper›PMID 30237624›Full record

ArticleReumatologia2018

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology.

Eugeniusz J Kucharz, Marcin Stajszczyk, Anna Kotulska-Kucharz, Bogdan Batko, Marek Brzosko, Sławomir Jeka, Piotr Leszczyński, Maria Majdan, Marzena Olesińska, Włodzimierz Samborski and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reumatologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Tofacitinib-induced progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Eugeniusz J KucharzDepartment of Internal Medicine, Rheumatology, and Clinical Immunology, Medical University of Silesia in Katowice, Poland.
Marcin StajszczykDepartment of Rheumatology and Autoimmune Diseases, Silesian Centre for Rheumatology, Rehabilitation, and Disability Prevention in Ustroń, Poland.
Anna Kotulska-KucharzDepartment of Internal Medicine, Rheumatology, and Clinical Immunology, Medical University of Silesia in Katowice, Poland.
Bogdan BatkoDepartment of Rheumatology, J. Dietl Memorial Specialist Hospital in Kraków, Poland.
Marek BrzoskoDepartment of Rheumatology, Internal Medicine, and Geriatrics, Pomeranian Medical University in Szczecin, Poland.
Sławomir JekaDepartment of Rheumatology and Systemic Connective Tissue Disorders, Jan Biziel University Hospital No. 2 in Bydgoszcz, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.
Piotr LeszczyńskiDepartment of Rheumatology and Rehabilitation, Poznań University of Medical Sciences, Poland.
Maria MajdanDepartment of Rheumatology and Systemic Connective Tissue Disorders, Medical University of Lublin, Poland.
Marzena OlesińskaClinic of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Włodzimierz SamborskiDepartment of Rheumatology and Rehabilitation, Poznań University of Medical Sciences, Poland.
Piotr WilandDepartment of Rheumatology and Internal Medicine, Wrocław Medical University, Poland.
Medical University of Silesia · PLPoznan University of Medical Sciences · PLMedical University of Lublin · PLNational Institute of Geriatrics, Rheumatology and Rehabilitation · PLNicolaus Copernicus University · PLPomeranian Medical University · PLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular nucleus and inhibits the inflammation process via a new pathway (inhibition of the Janus kinases), which is unavailable to biological medicines. Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic disease-modifying antirheumatic drug or in monotherapy. The efficacy of tofacitinib has been confirmed in several clinical trials. The drug inhibits radiographic progression of the disease. The innovative mechanism of action of tofacitinib is a noteworthy feature because it offers hope of effective treatment for patients who fail to respond to other drugs. The presented article discusses the mechanism of action and the clinical application of tofacitinib. Tofacitinib represents a new group of disease-modifying antirheumatic drugs that can be placed on an equal footing with biological drugs already available.

Indexed as

managementrheumatoid arthritistofacitinib

Identifiers

PMID30237624
PMCPMC6142023
OpenAlexW2891953208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.